Harry Dounis, DO
Nephrology · Neptune, NJNPI 1124286083
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,946 of the $75,288 with a category attached, or 77.0%. Vifor Pharma, Inc. accounts for 71.0% of it on its own, with 15 other manufacturers making up the rest. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $392.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$53K
- OPKO Pharmaceuticals, LLC$20K
- AstraZeneca$731
- Daiichi Sankyo Inc.$190
- Ardelyx, Inc.$179
- Amgen$162
- plus $922 from 10 others
What the payments were for
- Consulting fees$8,95312%
- Speaking & faculty fees$57,94677%
- Travel & lodging$3,4305%
- Food & beverage$4,8936%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 100 | $53,490 |
| OPKO Pharmaceuticals, LLC | 39 | $19,613 |
| AstraZeneca | 15 | $731 |
| Daiichi Sankyo Inc. | 9 | $190 |
| Ardelyx, Inc. | 5 | $179 |
| Amgen(2 entities) | 4 | $162 |
| Bayer | 5 | $158 |
| Aurinia Pharma U.S., Inc. | 2 | $157 |
| Baxter Healthcare | 1 | $150 |
| GSK | 3 | $132 |
| Otsuka America Pharmaceutical, Inc. | 1 | $114 |
| Travere Therapeutics, Inc. | 1 | $60 |
| Vantive US Healthcare LLC | 1 | $56 |
| Akebia Therapeutics Inc | 2 | $38 |
| Fresenius USA Marketing, Inc. | 3 | $37 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$44,454
- Rayaldee$19,163
- Korsuva$1,990
- FARXIGA$353
- Renal - Chronic$150
- LUPKYNIS$137
- XPHOZAH 30 MG$125
- INJECTAFER$124
- LOKELMA$123
- JYNARQUE$114
- Kerendia$110
- JESDUVROQ$101
How this compares
$75,288 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 133 | $155,035 |
| VeltassaPatiromer Calcium Sorbitex | 65 | $87,738 |
| KerendiaFinerenone | 48 | $81,786 |
| RayaldeeCalcifediol | 62 | $81,561 |
| JardianceEmpagliflozin | 57 | $79,210 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $22,569 |
| JanuviaSitagliptin Phosphate | 15 | $17,027 |
| EliquisApixaban | 19 | $13,783 |
| OzempicSemaglutide | 11 | $10,555 |
| Sevelamer Carbonate | 38 | $7,061 |
| Potassium Citrate ErPotassium Citrate | 37 | $6,510 |
| Valsartan | 184 | $5,159 |
| DapagliflozinDapagliflozin Propanediol | 12 | $4,614 |
| ProsolParenteral Amino Acid 20% No.1 | 35 | $3,578 |
| Torsemide | 194 | $3,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $731 | $177,604156 claims |
| BayerKerendia | $158 | $81,78648 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $19,613 | $81,56162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Neptune
- Arif AsifNeptune$42K
- Avais MasudNeptune$7K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Joseph AlbaneseBrick$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.